Atossa Therapeutics (NASDAQ:ATOS) Rating Increased to Hold at StockNews.com

Atossa Therapeutics (NASDAQ:ATOS – Free Report) was upgraded by stock analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday. Atossa Therapeutics Trading Down 1.6 % ATOS opened at $1.26 on Thursday. Atossa Therapeutics has a 12-month low of $0.50 and a 12-month […]

Related Keywords

,Charles Schwab Investment Management Inc ,Atossa Therapeutics Company Profile ,First Republic Investment Management Inc ,Atossa Therapeutics Inc ,Jpmorgan Chase Co ,Atossa Therapeutics ,Free Report ,Therapeutics Trading Down ,Republic Investment Management ,Schwab Investment Management ,Sigma Investments ,State Street Corp ,Street Corp ,Atossa Therapeutics Daily ,Nasdaq Atos ,Datos ,Medical ,Upgrade ,Stocknews Com ,